US Issues Recall of Shrimp Due to Radioactivity Concerns

U.S. health authorities have recalled shrimp imported from Indonesia due to potential contamination with radioactive cesium-137, emphasizing food safety concerns and the importance of monitoring imported seafood.
In an important public health update, U.S. authorities have announced the recall of certain frozen shrimp products over concerns related to potential radioactivity contamination. The recall implicates shrimp imported from Indonesia, specifically from a company named PT. Bahari Makmur Sejati. These products have been distributed across 13 states through retail giant Walmart.
The issue came to light after the detection of the radioactive isotope cesium-137 in some of the imported shrimp. While the levels of radioactivity found were minimal and posed no immediate health hazard, the Food and Drug Administration (FDA) emphasized the importance of caution. The agency clarified that none of the shrimp currently available in U.S. stores tested positive for radioactivity; however, the concern lies with the condition in which the shrimp was processed, packed, or stored.
Officials indicated that the shrimp may have been subjected to insanitary conditions that led to contamination, raising longer-term safety questions. Chronic exposure to low doses of cesium-137 has been associated with an increased risk of developing cancer over time.
In response, the FDA has urged Walmart to stage a recall and advised consumers who purchased the affected shrimp to dispose of it properly. Although the contamination levels are low, the recall underlines the importance of food safety monitoring in imported seafood.
This recall highlights the need for rigorous safety checks in the seafood supply chain and serves as a reminder for consumers to remain vigilant about the origins of their seafood products. For more details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Impact of the No Surprises Act: Significant Reduction in Patients' Out-of-Pocket Medical Expenses
A new study finds that the No Surprises Act enacted in 2022 has significantly lowered patients' out-of-pocket healthcare costs, saving nearly $600 annually per individual and reducing surprise billing among insured adults.
US Fertility Rate Hits Record Low in 2024, CDC Reports
New CDC data reveals the US fertility rate fell to a record low in 2024, signaling shifts in reproductive patterns amid economic and societal changes.
Increased Risk of Postpartum Hemorrhage Among Women from Ethnic Minority and Socioeconomically Deprived Backgrounds
Women from ethnic minority and socioeconomically deprived backgrounds face a higher risk of postpartum hemorrhage. This large-scale study underscores the need for targeted maternal health strategies to address disparities and improve outcomes worldwide.
Implications of Reclassifying Marijuana for Medical Research
Reclassifying marijuana from Schedule I to Schedule III could significantly enhance medical research, improve patient access, and promote industry growth by reducing current federal restrictions on cannabis studies.